Hypogonadism in patients with chronic obstructive pulmonary disease: relationship with airflow limitation, muscle weakness and systemic inflammation  by Daabis, Rasha Galal et al.
Alexandria Journal of Medicine (2016) 52, 27–33HO ST E D  BY
Alexandria University Faculty of Medicine
Alexandria Journal of Medicine
http://www.elsevier.com/locate/ajmeHypogonadism in patients with chronic obstructive
pulmonary disease: relationship with airﬂow
limitation, muscle weakness and systemic
inﬂammation* Corresponding author at: Department of Chest Diseases, Alexan-
dria Faculty of Medicine, Alazarita, 21311 Alexandria, Egypt. Tel.:
+20 35909701 (home), +20 1224582538 (mobile).
E-mail addresses: rgdaabis@yahoo.com, rgdaabis@gmail.com
(R.G. Daabis), ranianaguib2000@yahoo.com (R.N. Abdel Rehem),
drmarwamohamedhassan@yahoo.com (M.M. Hassan), gihane_
khalil2000@hotmail.com (G.I. Khalil).
1 Tel.: +20 1279594146 (mobile).
2 Tel.: +20 1002773457 (mobile).
3 Tel.: +20 1225259876 (mobile).
Peer review under responsibility of Alexandria University Faculty of
Medicine.
http://dx.doi.org/10.1016/j.ajme.2015.01.002
2090-5068 ª 2015 The Authors. Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Rasha Galal Daabis a,*, Rania Naguib Abdel Rehem b,1,
Marwa Mohamed Hassan c,2, Gihane Ibrahim Khalil d,3a Department of Chest Diseases, Faculty of Medicine, Alexandria University, Alexandria, Egypt
b Internal Medicine Department, Endocrinology Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt
c Department of Physical Medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Alexandria University,
Alexandria, Egypt
d Department of Chemical Pathology, Medical Research Institute, Alexandria University, EgyptReceived 22 August 2014; accepted 10 January 2015
Available online 24 February 2015KEYWORDS
Chronic obstructive pul-
monary diseases;
Hypogonadism;
Quadriceps muscle weakness;
Systemic inﬂammation;
Airﬂow obstruction;
Exercise capacityAbstract Objectives: To determine the prevalence of hypogonadism in male patients with Chronic
obstructive pulmonary diseases (COPD), and to study its impact on skeletal muscle dysfunction and
assess the effect of systemic markers of inﬂammation on testosterone level and muscle function. The
study included 50 stable male COPD patients and 30 controls.
Methods: Both groups were subjected to the following measurements; inﬂammatory markers levels
(high-sensitivity C-reactive protein (hs-CRP) and interleukin – 6 (IL-6)), sex hormones including;
serum total (T) and free testosterone (FT), sex hormone binding globulins (SHBG), luteinizing hor-
mone (LH), follicle-stimulating hormone (FSH) and 17b estradiol levels (E2), the exercise capacity
(6-minute walk distance (6MWT)) and quadriceps muscle force (One repetition maximum (1RM)
and EMG). COPD patients underwent spirometry.
Results: There was a higher prevalence of hypogonadism in COPD patients than the controls (62%
versus 17%). There was a signiﬁcant negative correlation between serum testosterone levels (T and
28 R.G. Daabis et al.FT) and the severity of airway obstruction. Quadriceps muscle force and the exercise capacity were
signiﬁcantly lower in COPD patients than controls but they showed no correlation with the testos-
terone level. Inﬂammatory markers were signiﬁcantly higher in COPD patients compared to con-
trols and showed a signiﬁcant correlation with the severity of airﬂow obstruction. The higher
inﬂammatory markers levels were related to more muscle weakness as hs-CRP was inversely corre-
lated with the quadriceps strength and exercise capacity, while IL-6 was inversely correlated to
quadriceps strength only.
Conclusion: Hypogonadism is highly prevalent in clinically stable COPD patients and is particular-
ly related to the severity of the airway obstruction. Systemic inﬂammation is present in stable
COPD patients and its intensity is related to the severity of the underlying disease and it predisposes
to skeletal muscle weakness and exercise intolerance. However, we failed to ﬁnd a signiﬁcant asso-
ciation between hypogonadism and muscle weakness or systemic inﬂammation.
ª 2015 The Authors. Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Chronic obstructive pulmonary disease (COPD) is a systemic
disease characterized by multiple extra pulmonary manifesta-
tions, including cachexia and skeletal muscle dysfunction
which can contribute to morbidity and mortality.1
Peripheral muscle dysfunction, a common systemic compli-
cation in patients with COPD, commonly results from muscle
wasting. This dysfunction is associated with decreased exercise
capacity, muscle weakness, impaired quality of life, and
decreased survival.2,3
The presence of a low-grade systemic inﬂammation can be
implicated in the pathogenesis of these extra pulmonary
manifestations including skeletal muscle dysfunction and
hypogonadism.4
It was observed that many patients with COPD, most of
whom are middle-aged or elderly, ﬁt the proﬁle of late-onset
hypogonadism5–7 manifested by diminished energy level,
libido, bone density, and muscle mass.8,9
Patients are deﬁned as being hypogonadal when they have
androgen deﬁciency combined with otherwise unexplained
fatigue or diminished energy, a diminished sense of vitality,
or a diminished sense of well-being (all commonly experienced
by patients with COPD).7–10
Prevalence of hypogonadism in men with COPD can range
from 22% to 69% and has been associated with several other
systemic manifestations including osteoporosis, depression,
and muscle weakness.11
Several observations suggest that hypogonadism may con-
tribute to themuscle dysfunction seen inmenwith COPD. First,
hypogonadism has a high prevalence among these patients. Sec-
ond, hypogonadism can cause decreases in nitrogen retention,
lean body mass, and body weight. Third, proinﬂammatory
cytokines, which are increased in some patients withCOPDwith
muscle wasting, can, lead to decreased testosterone production.
Fourth, testosterone deﬁciency can contribute to elevated levels
of interleukin-6, an inﬂammatory, procatabolic cytokine. Final-
ly, administration of testosterone can increase myoﬁbrillar pro-
tein synthesis and decrease protein breakdown.2
It has been observed that muscle weakness is not complete-
ly reversed even after long periods months of exercise train-
ing.12 Therefore, factors other than physical inactivity may
predispose to the development of muscle weakness in patients
with COPD.13,14Because of the clinical impression that systemic inﬂam-
mation as well as hypogonadism plays a signiﬁcant role in
the pathogenesis of skeletal muscle dysfunction in patients
with COPD, a case-control study was designed to determine
the prevalence of hypogonadism in a sample of male
patients with COPD, to study the impact of hypogonadism
on skeletal muscle dysfunction and to assess the effect of
systemic markers of inﬂammation on testosterone level and
muscle function.2. Subjects and methods
The present study is a case control study that was done in, Fac-
ulty of Medicine, Alexandria University, as a collaborate work
between pulmonary, internal medicine and physical medicine
departments, and medical research institute; department of
chemical pathology. The study protocol was approved by the
local ethics committee. Written informed consent according
to the hospital policy guidelines was obtained from all patients
and controls before initiating any study – related activity.2.1. Subjects
The study population consisted of 50 male patients with stable
COPD with no history of recent exacerbation and 30; age-
matched, healthy control subjects. The diagnosis of COPD
was based on smoking history and on pulmonary function test
results showing irreversible airﬂow limitation.15 All patients
were subjected to thorough history taking, including treatment
proﬁle and complete physical examination.2.1.1. Exclusion criteria
Included comorbidities which may interfere with the results of
the sex hormones proﬁle (e.g. prostate carcinoma, liver cirrho-
sis) and current androgen and anti-androgen therapy. Any
chronic diseases, such as chronic heart failure or diabetes,
active inﬂammatory diseases or primary diagnosis of obstruc-
tive sleep apnea syndrome. Subjects who received systemic
steroids within the 4 months prior to the study. Patients with
Hemoglobin level less than 13 g were excluded from the study
to rule out the effect of anmia on sex hormone level or muscle
function.
Table 1 Characteristics and pulmonary function tests of the
studied groups.
COPD Controls P value
Age 55.75 ± 4.03 53.24 ± 3.3 NS
Smoking status, n (%)
Current smoker 29(58) 15(50)
Ex-smoker 19(38) 11(37)
Never smoker 2(4) 4(13) NS
BMI (kg/m2) 24.87 ± 7.3 21.57 ± 2.6 NS
Hb level (g%) (14.0 ± 0.7) 15.0 ± 0.3) NS
Hypogonadism in patients with chronic obstructive pulmonary disease 292.2. Laboratory Investigations:
Samples were collected in fasting state in the morning. Sample
collection, processing, and storage were done according to the
kits instructions. The following measurements were done:
2.2.1. Markers of systemic inﬂammation:
Including high sensitivity CRP (hs-CRP) using a high sensi-
tivity latex assay (lower limit of detection 6 0.79 mg/dl) on
the Olympus autoanalyzer and IL-6 by Enzyme-Linked
Immunosorbant assay (ELISA) using a commercially available
kit Immunodiagnostic AG, Stubenwold-Alke 8a D64625 Ben-
shemin according to manufacturer’s instructions.
2.2.2. Sex hormones:
Serum concentrations of free testosterone (FT), total testos-
terone (T), sex hormone binding globulins (SHBG), luteinizing
hormone (LH), follicle-stimulating hormone (FSH) and 17b
estradiol levels (E2) using chemiluminescence technique
(IMMULITE 2000 analyzer).
2.3. Six-minute walking distance:
A six-minute walking test was performed according to stan-
dard procedure and was used as a measure of exercise capacity.
Patients were asked to walk on a 20 m course over a 6 min
period. Then the distances covered by the patients during this
time interval minutes were recorded.16
2.4. Pulmonary function tests:
All patients underwent standard spirometry before and after
bronchodilator inhalation according to American Thoracic
Society/European Respiratory Society standards.17
2.5. Quadriceps muscle force:
One repetition maximum (1RM) was assessed for the quadri-
ceps muscle. This was done using knee extension machine with
pelvic strap. Subjects were asked to do few repetitions of knee
extension to warm-up. After that, a resistance that is thought
to be slightly less than 1RM value was chosen and the subject
performed knee extension for one repetition. Subjects were left
to rest for one minute then another trial was done against a
higher resistance until the true 1RM value was achieved.18
2.6. Electromyography (EMG):
Needle EMG was done for the quadriceps muscle (rectus
femoris). Rest potentials and motor unit action potentials
(MUAP) were assessed.COPD level of severity, n (%)
Mild 2(4)
Moderate 10(20)
Severe 32(64)
Very severe 6(12) – –
FEV1 (L) 1.2 ± 0.5 – –
FEV1 (%) 36.4 ± 13.24 – –
FEV1/FVC 56 ± 20.6 – –2.7. Statistical analysis
Data were collected, tabulated, then analyzed using SPSS
Ver.13. Qualitative data were presented as numbers and per-
centage. Quantitative data were expressed as means and stan-
dard deviation. Differences between the groups were analyzed
by using the student’s unpaired t-test and v2 tests where appro-priate. Correlations between different parameters were
evaluated using Pearson’s rank correlation analysis. A 5%
level was chosen as a level of signiﬁcance in all statistical tests
used in the study.
3. Results
3.1. Patient’s characteristics and routine labs
Patients with COPD had mean ± SD age of (55.75 ± 4.03)
while it was (53.24 ± 3.3) in the control group. Twenty-nine
patients (58%) were current smokers, 19 (38%) were ex-smok-
ers and 2 (4%) were never smoker. BodyMass index (BMI) was
(24.87 ± 7.3) in COPD group compared to (21.57 ± 2.6) in the
control group. Patients with COPD had Hemoglobin level (Hb)
of (14.0 ± 0.7) while it was (15.0 ± 0.3) in the control group.
There was no signiﬁcant difference regarding age, smoking sta-
tus, BMI or hemoglobin level in both groups. Two patients had
mild COPD, 10 moderate. 32 severe and 6 patients suffered
very severe COPD15 (Table 1).
3.2. Hormonal proﬁle
COPD patients had signiﬁcantly lower levels of total testos-
terone, free testosterone in COPD patients compared to con-
trol group with a p value of 0.004 and 0.015, respectively.
On the other hand the SHBG was signiﬁcantly higher in
COPD patients (P= 0.003). However, there was no signiﬁcant
difference between mean serum (E2) level in COPD patients
(40.8 ± 6.5) pg/ml and control group (33.7 ± 10.4) pg/ml
(p= 0.057), While Estrogen/Testosterone ratio (E2/T ratio)
was signiﬁcantly higher in COPD group (9.5 ± 2.4) compared
to control group (5 ± 1.5) (p< 0.001). Out of the 50 patients
with COPD, 30 patients (60%) were hypogonadal (free testos-
terone < 50 pg/ml) (16) Table 1. Out of them 22 patients
(74%) showed low levels of FSH and LH suggesting hypo
gonadotrophic hypogonadism. the remaining 8 (27%) patients
showed picture of testicular dysfunction (low serum level of
testosterone with high serum levels of FSH and LH). The
prevalence of hypogonadism in COPD patients was sig-
Table 2 Hormonal proﬁle of the studied groups.
COPD Controls P value
Total testosterone, ng/ml 4.5 ± 1.3 7.1 ± 2.3 0.004*
Free testosterone, pg/ml 48.2 ± 10.2 59.6 ± 11.4 0.015*
Hypogonadism, n (%) 30 (60) 5 (17) 0.03*
SHBG, nmol/l 74.9 ± 9.3 57.4 ± 34.6 0.003*
E2 pg/ml 40.8 ± 6.5 33.7 ± 10.4 0.057
E2/T 9.5 ± 2.4 5 ± 1.5 <0.001
*
* Statistically signiﬁcant at p< 0.05.
30 R.G. Daabis et al.niﬁcantly higher than in the control group; 60% versus 17%
with a p value of 0.03. In COPD patients, 22 (73%) had con-
centration for FSH signiﬁcantly lower than control group
(2.3 ± 0.9) mIU/mL versus (4.6 ± 1.2) mIU/mL which signi-
ﬁes hypogonadotropin hypogonadism, while 8 patients
(26%) showed signiﬁcantly higher FSH levels of
(7.9 ± 3.2) mIU/mL compared to the control group. LH levels
in 74% of COPD patients were signiﬁcantly lower
(2.4 ± 0.9) mIU/mL compared to the control group
(3.3 ± 1.2) mIU/mL. Eight (8) patients (22%) showed sig-
niﬁcantly higher LH levels (6.9 ± 2.1) compared to control
group (Table 2).
3.3. Inﬂammatory markers
Hs-CRP levels were signiﬁcantly higher in COPD patients
(10.7 ± 3.4) mg/l compared to control group (2.3 ± 1.1)
(p< 0.001).
IL-6 levels were signiﬁcantly higher in COPD patients
(10.7 ± 1.9) ng/ml compared to control group (2.5 ± 0.85)
(p< 0.001) (Table 3).
3.4. Quadriceps muscle force and six minute walk test (6MWT)
The mean 1RM in COPD group was (8.3 ± 5.1) kg which was
signiﬁcantly lower than control group (29.5 ± 4.8) kg
(p< 0.001). Also the 6-min walking distance (6MWT) was sig-
niﬁcantly lower in COPD group (246.1 ± 148.6) m compared
to the control group (571 ± 90) m. (p= 0.003) (Table 3).
3.5. Electromyography (EMG)
Out of 50 stable male COPD patients, 13 patients (26%)
showed abnormal rest potentials and 25 patients (50%)
showed myopathic MUAPs (Table 3).Table 3 Inﬂammatory markers, quadriceps muscle force and
six minute walk test (6MWT) in the studied groups.
COPD Controls P value
Hs-CRP, mg//l 10.7 ± 3.4 2.3 ± 1.1 <0.001*
IL-6, ng/ml 10.7 ± 1.9 2.5 ± 0.85 <0.001*
1RM, kg 8.3 ± 5.1 29.5 ± 4.8 <0.001*
6 MWT, m 246.1 ± 148.6 571 ± 90 0.003*
Abnormal rest potentials n (%) 13 (26) None –
Myopathic MUAPs n (%) 25 (50) None –
* Statistically signiﬁcant at p< 0.05.3.6. Correlation between hormonal proﬁle and Pulmonary
function tests
Serum testosterone level showed a signiﬁcant positive correla-
tion with both FEV1 (r= 0.558, p= 0.031) and FEV1/FVC
ratio (r= 0.828, p= 0.003). Serum free testosterone level
showed a signiﬁcant positive correlation with FEV1 only
(r= 0.675, p= 0.032). E/T ratio was negatively correlated
with FEV1 (r= 0.586, P= 0.022).
3.7. Correlation between hormonal proﬁle and Quadriceps
muscle force
There was no signiﬁcant correlation between the hormonal
proﬁle of COPD patients and quadriceps muscle strength
(1RM) or the exercise capacity (6MWT).
3.8. Correlation between inﬂammatory markers and pulmonary
function tests
There was a signiﬁcant negative correlation between hs-CRP
and FEV1/FVC (r= 0.332, p= 0.037) and between IL6
and FEV1% (r= 0.596, p= 0.002).
3.9. Correlation of inﬂammatory markers with quadriceps
muscle force and six minute walk test (6MWT)
1RM was signiﬁcantly inversely correlated with hs-CRP and
IL-6 (r= 0.371, p= 0.021 and r= 0.412, p= 0.008
respectively).
CRP was signiﬁcantly inversely correlated with 6MWT
(r= 0.311, p= 0.036).
3.10. Correlation between hormonal proﬁle and inﬂammatory
markers
There was no correlation between serum testosterone, free
testosterone, SHBG levels or E2/T ratio and any of the inﬂam-
matory markers. There was no correlation between FSH or
LH and systemic markers of inﬂammation.
There was no signiﬁcant correlation between the sex hor-
mones and other parameters such as age, smoking status,
BMI or hemoglobin level.
4. Disscusion
In the present study, we found signiﬁcant differences in serum
levels of sex hormones between male patients with COPD and
age matched healthy males. In addition there was a higher
prevalence of hypogonadism in the COPD patients than the
control subjects (62% versus 17%). Prevalence estimates of
low testosterone vary with the deﬁnition used, the population
studied, and method of analysis used. It was estimated in the
Massachusetts Male Aging Study that approximately 6% of
40–69-year-old US men have symptomatic testosterone deﬁ-
ciency.19 Prevalence estimates from other studies that did not
consider signs and symptoms varied from 10% to 25% of
the general population.19–22 Prevalence of hypogonadism in
men with COPD also varied among studies, ranging from
22% to 69%.3,7,11,22,23
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study. Debigare et al.3 reported that 10 of 45 (22%) patients
were hypogonadal. Monique Van Vliet et al.22 reported that
(52%) of their patients had hypogonadism. Laghi et al.7
reported a percentage of (38%) hypogonadism in their study.
This difference may be explained by ethnic factors or due to
difference in patients’ selection.
COPD patients had signiﬁcantly lower levels of FSH and
LH compared to control group (p= 0.002, r= 0.243 and
p= 0.001, r= 0.351) respectively. Out of the 50 COPD
patients, 22 (73%) showed low levels of FSH and LH. This
can be explained by impaired function of the hypothalamic –
pituitary gonadal axis in patients with COPD. These results
are matching with the results obtained by Laghi et al.7 who
reported that (76%) of the hypogonadal COPD patients had
hypo gonadotrophic hypogonadism. These ﬁndings can be
explained by an impairment of the release of the hypothalamic
hormones, malfunction of the released hormones, loss of feed-
back control mechanism, or a combination of all of them.
Some other mechanisms, including chronic disease, hypox-
emia, glucocorticoid therapy, and obesity can cause hypo
gonadotrophic hypogonadism.22,24–26
The remaining 8 patients showed picture of testicular dys-
function. These results are compatible with results of Laghi
et al.7 who reported testicular dysfunction in quarter of their
patients. This can be explained by atrophy of Leydig cells,27
circulating cytokines,28,29 and use of steroids.29,30
SHBG was signiﬁcantly higher in COPD group compared
to control group. Despite the fact that aging has been shown
to increase the circulating SHBG concentrations, the age was
similar in both COPD and control groups so it cannot explain
the increase in SHBG. This may therefore be explained by the
low circulating free testosterone concentrations encountered in
the COPD patients.22
In our study, serum total testosterone level showed a sig-
niﬁcant positive correlation with both FEV1 and FEV1/FVC
ratio (p= 0.031 and 0.003 respectively). Serum free testos-
terone level showed a signiﬁcant positive correlation with
FEV1 (p= 0.032). E2/T ratio was negatively correlated with
FEV1 (p= 0.022). This signiﬁcant correlation between the
testosterone levels and the severity of airway obstruction fur-
ther supports the fact that the high prevalence of hypogonad-
ism in COPD patients is related to the pathogenesis of the
disease and is different from the late-onset hypogonadism that
occurs in the general population. Chronic illnesses such as dia-
betes mellitus, CVD and hypertension have been associated
with a decline in serum testosterone. COPD is a chronic illness
and hence may manifest testosterone deﬁciency.31 Our results
are similar to Karadag et al. who studied a group of stable
COPD and patients in an exacerbation and found that Testos-
terone and DHEAS levels were lower in severe COPD (FEV1
less than 50%) and detected a positive correlation between
testosterone and FEV1. Makarevich et al.10 assessed relation
of sex hormone status and the stage of COPD. They concluded
that the intensity of sex hormone changes was correlated with
the stage of COPD. As the severity of disease increased, testos-
terone decreased while LH, FSH increased in compensation.
Also, Shaker et al. who studied the sex hormones level in
COPD patients during exacerbation and after 1 m found that
the low levels of serum testosterone found in these patients
was signiﬁcantly correlated to the severity of airway obstruc-
tion as measured by FEV1%.32However, other studies have failed to report similar asso-
ciations as Laghi et al.7 and Van Vliet et al.22 who found no
relationship between free testosterone level and degree of air-
ﬂow limitation (FEV1), this could be due to different patients’
selection criteria or presence of other comorbidities.
In the present study, Quadriceps muscle force was sig-
niﬁcantly lower in COPD patients than in the control group
(p= 0.001). Moreover, the exercise capacity (6-min walk dis-
tance) was signiﬁcantly less in COPD patients than the control
group (p= 0.003). These results are consistent with previous
reports.22 The mechanisms of skeletal muscle dysfunction in
COPD patients could be explained by physical inactivity,33,34
chronic low-grade systemic inﬂammation,22 malnutrition,
medication, age, hypoxemia and smoking.
Our results showed that there was no correlation between
serum testosterone level and quadriceps muscle force or with
exercise capacity (6-min walk distance) in patients with COPD.
These results are similar to previous studies.3,9 For instance,
Debigare and associates (3) reported that the prevalence of
hypogonadism among men with COPD is equivalent among
patients with and without muscle wasting. Similarly, Laghi
et al. found that quadriceps strength (and endurance) were
similar in hypogonadal and eugonadal men with COPD. In
their study, Van Vliet et al.22 found a signiﬁcant correlation
between testosterone concentrations and quadriceps strength.
This ﬁnding added more confusion to the available conﬂicting
results.2,22,35,36 The explanation of these contradictory results
regarding the effect of hypodonadism on muscle weakness is
not clear; moreover the studies who found a correlation
between the testosterone level and the degree of muscle weak-
ness did not show a high statistical signiﬁcance that could be of
clinical importance.9
Inﬂammatory markers levels including hs-CRP and IL-6
were signiﬁcantly higher in COPD patients compared to con-
trol group (p< 0.001). Numerous studies performed in recent
years provide overwhelming evidence of COPD as a condition
characterized by an abnormal inﬂammatory response beyond
the lungs with evidence of low-grade systemic inﬂamma-
tion.37–41 Raised levels of acute phase proteins like CRP, ﬁb-
rinogen and pro-inﬂammatory cytokines such as IL-6 were
found in circulation of stable COPD patients38 and have been
shown to be associated with impaired functional capacity,42
reduced daily physical activity43 and decreased health
status.40,44
In our study we found a signiﬁcant correlation between the
inﬂammatory markers (hs-CRP and IL6) and the severity of
airﬂow obstruction (p= 0.037 and 0.002 respectively). It is
well established now that systemic inﬂammation is present in
stable COPD patients and that its intensity is related to the
severity of the underlying disease.37–40 Moreover, we found
that CRP was inversely correlated with the quadriceps strength
as measured by the one repetition maximum as well as the
exercise capacity as measured by the 6 min walk distance
P= 0.021 and p= 0.036) respectively, also we found that
IL6 was inversely correlated to quadriceps strength
(P= 0.008). Our results indicate that systemic inﬂammation
in COPD predisposes to skeletal muscle weakness and exercise
intolerance in stable COPD patients. In consistence with our
results, Yende et al. in their study45 on 2273 elderly indi-
viduals, where the pulmonary function testing revealed that
12% of them had COPD, found that the degree of airﬂow
obstruction, as measured by the FEV1, was signiﬁcantly
32 R.G. Daabis et al.associated with the degree of muscle weakness. They also
found that systemic inﬂammation as measured by the level
of IL-6, was more in patients with COPD and was related to
airﬂow obstruction, muscle weakness and exercise intolerance.
Also Broekhuizen et al.46 studied 102 patients with severe
to very severe COPD, nearly 33% of which were on systemic
corticosteroids, who were admitted to an inpatient pulmonary
rehabilitation center. They found that reduced FEV1 was cor-
related with increased plasma levels of CRP and IL-6, conﬁrm-
ing that the severity of airﬂow limitation is associated with
systemic inﬂammation. Their results are in concordance with
previous results showing that raised CRP levels were associat-
ed with diminished muscle strength, reduced exercise endur-
ance, workload, 6 min walk distance, and poor health status
and quality of life.
Systemic inﬂammation has been suggested as a possible
cause of hypoandrogenemia in male patients with COPD.
However, until now, only a weak signiﬁcant inverse relation-
ship between the circulating levels of IL-6 and bioavailable
testosterone has been found in COPD male patients
(r= 0.33).3 In the present study we found no signiﬁcant corre-
lation between the low testosterone and markers of systemic
inﬂammation (hs-CRP and IL-6). Our results are similar to
Karadag et al.47 who studied 103 COPD patients for sex hor-
mone alterations along with inﬂammatory markers (TNF-a
and IL-6). The study group comprised stable COPD patients
and patients undergoing a COPD exacerbation. Although
sex hormones were lower and circulating IL-6 and TNF-a con-
centrations were higher in both stable and exacerbation phase
COPD groups than controls, there was no correlation between
sex hormones and TNF-a or IL-6. Hence, there is no current
evidence to support inﬂammation as a contributor to testos-
terone deﬁciency in COPD.
In conclusion hypogonadism is highly prevalent in clinically
stable COPD patients and is particularly related to the severity
of the airway obstruction. Therefore, regular screening COPD
patients for the sex hormone level seem justiﬁed. Furthermore,
we conﬁrmed that systemic inﬂammation exists in stable COPD
and that the intensity of the inﬂammatory process relates to the
severity of the underlying disease and that systemic inﬂamma-
tion in COPD is a risk factor for peripheral muscle weakness
and reduced exercise tolerance. However, we failed to ﬁnd a sig-
niﬁcant association between hypogonadism and muscle weak-
ness or systemic inﬂammation. Future research in this area is
needed to shed more light on this matter especially on the role
of testosterone replacement therapy in the prevention of hypo-
gonadism and in delaying muscle weakness in COPD patients.
Moreover, further investigations could be done to study the
effect of other parameters on the occurrence of hypogonadism
and the degree of muscle weakness in these patients for example
the degree of hypoxemia or hypercapnea as well as electrolyte
disturbance and serum uric acid levels.
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